You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School
Boehringer Ingelheim

Last Updated: September 18, 2020

DrugPatentWatch Database Preview

Patent: 9,458,168

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,458,168
Title:Bicyclic-fused heteroaryl or aryl compounds
Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, ##STR00001## as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
Inventor(s): Trzupek; John David (Medford, MA), Lee; Katherine Lin (West Newton, MA), Bunnage; Mark Edward (Concord, MA), Han; Seungil (Mystic, CT), Hepworth; David (Concord, MA), Lovering; Frank Eldridge (Acton, MA), Mathias; John Paul (Concord, MA), Papaioannou; Nikolaos (Boston, MA), Strohbach; Joseph Walter (Wentzville, MO), Wright; Stephen Wayne (Old Lyme, CT), Zapf; Christoph Wolfgang (Marlborough, MA), Gavrin; Lori Krim (Villanova, PA), Lee; Arthur (Gaithersburg, MD), Curran; Kevin Joseph (Somerset, NJ), Dehnhardt; Christoph Martin (Burnaby, CA), Saiah; Eddine (Brookline, MA), Goldberg; Joel Adam (New Orleans, LA), Wang; Xiaolun (San Diego, CA), Vargas; Richard (Bedford, MA), Lowe; Michael Dennis (White Plains, NY), Patny; Akshay (Waltham, MA)
Assignee: Pfizer Inc. (New York, NY)
Application Number:14/678,114
Patent Claims:see list of patent claims

Details for Patent 9,458,168

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Centocor Inc REMICADE infliximab VIAL 103772 001 1998-08-24   Start Trial Pfizer Inc. (New York, NY) 2039-02-26 RX Orphan search
Immunex ENBREL etanercept VIAL; SUBCUTANEOUS 103795 001 1998-11-02   Start Trial Pfizer Inc. (New York, NY) 2039-02-26 RX Orphan search
Immunex ENBREL etanercept SYRINGE 103795 002 1998-11-02   Start Trial Pfizer Inc. (New York, NY) 2039-02-26 RX Orphan search
Abbvie Inc HUMIRA adalimumab SYRINGE 125057 001 2002-12-31   Start Trial Pfizer Inc. (New York, NY) 2039-02-26 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.